What is HC Wainwright's Forecast for YMAB FY2026 Earnings?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Investment analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for shares of Y-mAbs Therapeutics in a research note issued on Monday, May 19th. HC Wainwright analyst R. Burns forecasts that the company will post earnings per share of ($0.92) for the year. HC Wainwright has a "Buy" rating and a $11.00 price objective on the stock. The consensus estimate for Y-mAbs Therapeutics' current full-year earnings is ($0.65) per share.

Other equities research analysts have also recently issued reports about the company. Oppenheimer reduced their price objective on Y-mAbs Therapeutics from $21.00 to $20.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 14th. Morgan Stanley cut their target price on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a research report on Wednesday, March 5th. Truist Financial decreased their price target on Y-mAbs Therapeutics from $18.00 to $14.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Wedbush reaffirmed an "outperform" rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. Finally, Bank of America cut shares of Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price objective on the stock. in a research report on Tuesday, April 22nd. Two investment analysts have rated the stock with a sell rating, seven have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Y-mAbs Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $16.60.

Y-mAbs Therapeutics Price Performance

Shares of NASDAQ YMAB traded up $0.19 during mid-day trading on Tuesday, hitting $4.32. 324,293 shares of the company's stock traded hands, compared to its average volume of 312,434. The company's 50-day moving average is $4.41 and its two-hundred day moving average is $6.68. The company has a market capitalization of $195.63 million, a P/E ratio of -8.00 and a beta of 0.53. Y-mAbs Therapeutics has a 1 year low of $3.55 and a 1 year high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.10. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The company had revenue of $20.90 million for the quarter, compared to the consensus estimate of $19.97 million.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Large investors have recently modified their holdings of the business. Wells Fargo & Company MN lifted its position in Y-mAbs Therapeutics by 54.1% during the fourth quarter. Wells Fargo & Company MN now owns 17,458 shares of the company's stock valued at $137,000 after purchasing an additional 6,131 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Y-mAbs Therapeutics by 10.4% in the third quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company's stock worth $399,000 after acquiring an additional 2,854 shares during the last quarter. Geode Capital Management LLC boosted its stake in Y-mAbs Therapeutics by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 822,309 shares of the company's stock worth $6,440,000 after purchasing an additional 8,820 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Y-mAbs Therapeutics by 1.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 284,540 shares of the company's stock valued at $2,228,000 after acquiring an additional 4,963 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Y-mAbs Therapeutics in the fourth quarter valued at approximately $46,000. Hedge funds and other institutional investors own 70.85% of the company's stock.

Insider Transactions at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 10,810 shares of the company's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $5.23, for a total value of $56,536.30. Following the completion of the sale, the insider now directly owns 202,721 shares in the company, valued at approximately $1,060,230.83. This represents a 5.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 22.50% of the company's stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.